Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized global pivotal phase 3 clinical trial of Furmonertinib in first-line NSCLC in patients across PACC mutations

Next Previous
Trial Profile

A randomized global pivotal phase 3 clinical trial of Furmonertinib in first-line NSCLC in patients across PACC mutations

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 27 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Firmonertinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ALPACCA

Most Recent Events

  • 27 Jun 2025 New trial record
  • 23 Jun 2025 According to an ArriVent Biopharma media release, this trial has been designed with extensive regulatory input. Trial design enables potential for both accelerated and full approval. Firmonertinib 240 mg selected as the optimal dose for pivotal Phase 3 development. Enrollment of first patient in ALPACCA (FURMO-006) is expected in the second half of 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top